Improved mouse models for the study of treatment modalities for immune‐mediated platelet destruction

BACKGROUND: We found when using a mouse model of immune thrombocytopenia (ITP) that platelet (PLT) nadir could not be maintained in the face of daily PLT antibody, making interpretation of treatment modalities difficult. This finding was documented to be at least in part due to increased thrombopoiesis as a result of a compensated thrombocytolytic state. Thus, it was important to develop an improved mouse model of human ITP so as to maintain PLT nadir over time.

[1]  R. Calabrese,et al.  Long‐term follow‐up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response , 2009, British journal of haematology.

[2]  J. Balthasar,et al.  Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia. , 2007, Blood.

[3]  J. Ravetch,et al.  Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation , 2006, Science.

[4]  Shimon Sakaguchi,et al.  Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune disease , 2006, Immunological reviews.

[5]  J. Freedman,et al.  Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. , 2006, Nature medicine.

[6]  J. Freedman,et al.  Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. , 2005, Blood.

[7]  J. Freedman,et al.  Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? , 2005, The Journal of clinical investigation.

[8]  A. Shad,et al.  Treatment of Immune Thrombocytopenic Purpura in Children , 2005, Paediatric drugs.

[9]  A. Shad,et al.  Treatment of immune thrombocytopenic purpura in children : current concepts. , 2005, Paediatric drugs.

[10]  A. Panasiuk,et al.  Reticulated platelets as a marker of megakaryopoiesis in liver cirrhosis; relation to thrombopoietin and hepatocyte growth factor serum concentration. , 2004, Hepato-gastroenterology.

[11]  K. Siminovitch,et al.  IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. , 2003, Blood.

[12]  J. Freedman,et al.  Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. , 2003, Blood.

[13]  I. Khouri,et al.  Immune Thrombocytopenic Purpura , 2018 .

[14]  J. Freedman,et al.  IVIg inhibits reticuloendothelial system function and ameliorates murine passive‐immune thrombocytopenia independent of anti‐idiotype reactivity , 2001, British journal of haematology.

[15]  C. Hack,et al.  Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. , 2001, Blood.

[16]  W. Vainchenker,et al.  Different expression of CD41 on human lymphoid and myeloid progenitors from adults and neonates. , 2001, Blood.

[17]  J. Ravetch,et al.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. , 2001, Science.

[18]  R. Mcmillan.  Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. , 2000, Seminars in hematology.

[19]  I. Weissman,et al.  The monoclonal antibody TER‐119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage , 2000, British journal of haematology.

[20]  V. Blanchette,et al.  Intravenous immunoglobulin G and anti-D as therapeutic interventions in immune thrombocytopenic purpura. , 1998, Transfusion science.

[21]  C. Begley,et al.  Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis. , 1997, Blood.

[22]  Mcdonald Tp,et al.  C3H mice have larger spleens, lower platelet counts, and shorter platelet lifespans than C57BL mice: an animal model for the study of hypersplenism. , 1997 .

[23]  K. Siminovitch,et al.  Flow cytometric analysis of platelets from childrenwith the Wiskott‐Aldrich syndrome reveals defects in platelet development, activation and structure , 1997, British journal of haematology.

[24]  T. McDonald,et al.  C3H mice have larger spleens, lower platelet counts, and shorter platelet lifespans than C57BL mice: an animal model for the study of hypersplenism. , 1997, Experimental hematology.

[25]  J. Bussel,et al.  Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: insight into the regulation of platelet production. , 1996, Blood.

[26]  J. George,et al.  Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. , 1996, Blood.

[27]  K. Ault,et al.  In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. , 1995, Experimental hematology.

[28]  R. Hillman,et al.  The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. , 1992, American journal of clinical pathology.

[29]  J. Bussel.  The use of intravenous γ-globulin in idiopathic thrombocytopenic purpura , 1989 .

[30]  P. Stenberg,et al.  Ultrastructural analysis of acute immune thrombocytopenia in mice: Dissociation between alterations in megakaryocytes and platelets , 1989, Journal of cellular physiology.

[31]  V. Gallicchio.  Accelerated Recovery of Hematopoiesis Following Sub‐Lethal Whole Body Irradiation With Recombinant Murine Interleukin‐1 (IL‐1) , 1988, Journal of Leukocyte Biology.

[32]  J. Bussel,et al.  THE USE AND MECHANISM OF ACTION OF INTRAVENOUS IMMUNOGLOBULIN IN THE TREATMENT OF IMMUNE HAEMATOLOGIC DISEASE , 1984, British journal of haematology.

[33]  A. Hirt,et al.  Intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP) in childhood. , 1984, The American journal of pediatric hematology/oncology.

[34]  A. Hirt,et al.  High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. , 1981, Helvetica paediatrica acta.

[35]  R. Ar.  Compensated thrombocytolytic state. , 1980 .

[36]  A. R. Rodriguez.  Compensated thrombocytolytic state. , 1980, Southern medical journal.

[37]  S. Karpatkin,et al.  Autoimmune thrombocytopenic purpura and the compensated thrombocytolytic state. , 1971, The American journal of medicine.

[38]  R. Penny,et al.  The splenic platelet pool. , 1966, Blood.